Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Unit price / market price
-
$0.6560
-
Total 13F principal
-
$212,353,242
-
Principal change
-
-$19,641,000
-
Total reported value
-
$139,496,291
-
Number of holders
-
21
-
Value change
-
-$15,500,337
-
Number of buys
-
10
-
Number of sells
-
5
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2024
As of 30 Jun 2024 REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 had 21 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $212,353,242 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included D. E. Shaw & Co., Inc., OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), Graham Capital Management, L.P., Nuveen Asset Management, LLC, SILVERBACK ASSET MANAGEMENT LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, SSI INVESTMENT MANAGEMENT LLC, MORGAN STANLEY, Walleye Capital LLC, and AMUNDI.
This table shows 21 bond principal holders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.